Covidien (COV) Earns Daily Coverage Optimism Rating of 0.19

News stories about Covidien (NYSE:COV) have trended somewhat positive this week, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Covidien earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned news coverage about the healthcare company an impact score of 45.9654673191844 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:

How to Become a New Pot Stock Millionaire

Shares of Covidien stock remained flat at $$106.71 during midday trading on Monday. Covidien has a 12 month low of $65.97 and a 12 month high of $108.57.

ILLEGAL ACTIVITY NOTICE: “Covidien (COV) Earns Daily Coverage Optimism Rating of 0.19” was first published by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3344245/covidien-cov-earns-daily-coverage-optimism-rating-of-0-19.html.

Covidien Company Profile

Covidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company’s brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries.

Insider Buying and Selling by Quarter for Covidien (NYSE:COV)

Receive News & Ratings for Covidien Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covidien and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Eli Lilly and  Given a $80.00 Price Target at Credit Suisse Group
Eli Lilly and Given a $80.00 Price Target at Credit Suisse Group
First Solar  Given a $90.00 Price Target at Roth Capital
First Solar Given a $90.00 Price Target at Roth Capital
Summit Midstream  Given a $17.00 Price Target by SunTrust Banks Analysts
Summit Midstream Given a $17.00 Price Target by SunTrust Banks Analysts
Burlington  Given a $148.00 Price Target by SunTrust Banks Analysts
Burlington Given a $148.00 Price Target by SunTrust Banks Analysts
Piper Jaffray Reiterates Hold Rating for Akorn
Piper Jaffray Reiterates Hold Rating for Akorn
Avangrid  Issues FY18 Earnings Guidance
Avangrid Issues FY18 Earnings Guidance


Leave a Reply

© 2006-2018 Ticker Report. Google+.